Premium
Teva Pharmaceutical Industries Ltd (TEVA)
NYSE
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three se... Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three segments: North America, Europe and International Markets. Each business segment manages a product portfolio in its region, including generics, which include biosimilars and over-the-counter products, as well as innovative medicines. Show more
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023;AUSTEDO® - exceeding $1.6 billion in revenues, surpassing 2024 outlook;AJOVY® - global annual...
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1Agreement builds on the proven and successful collaboration...
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG...
TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the...
TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full...
Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD)Primary endpoint results in UC and CD for high dose represent...
Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinicsThe program, launching this month, will run for a minimum of three years PARSIPPANY...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -4.06 | -18.623853211 | 21.8 | 22.3999 | 17.5143 | 22219944 | 19.29711013 | DR |
| 4 | -3.66 | -17.1028037383 | 21.4 | 22.3999 | 17.5143 | 13366845 | 20.36481118 | DR |
| 12 | 0.33 | 1.89546237794 | 17.41 | 22.8 | 16.15 | 11051772 | 19.50955779 | DR |
| 26 | 0.44 | 2.54335260116 | 17.3 | 22.8 | 15.81 | 8940920 | 18.74046556 | DR |
| 52 | 6.07 | 52.0137103685 | 11.67 | 22.8 | 11.62 | 9404767 | 16.69884488 | DR |
| 156 | 9.47 | 114.510278114 | 8.27 | 22.8 | 6.7791 | 10036200 | 11.37929359 | DR |
| 260 | 7.49 | 73.0731707317 | 10.25 | 22.8 | 6.25 | 10293300 | 10.89483801 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
